Iain Jordan - What Did Clinical Trials Teach Us About Risks in Psychedelic-Assisted Therapy?

Psychedelic-assisted therapy relies heavily on rigorous clinician selection to mitigate the inherent risks posed by potent and destabilizing substances. While often touted as very safe, these treatments carry physiological side effects, such as cardiovascular shifts, alongside psychological risks like distressing experiences or reactivations. The success of treatment often hinges on the quality of the therapeutic container, including the practitioner's skill level and the broader support systems available within the clinical environment. Practical management of these risks requires a first-principles approach rather than relying solely on insufficient existing evidence. Effective clinical trial protocols must address challenges like context mismatch, where an individual's psychedelic experience contrasts sharply with their home reality. Additionally, clinicians should be prepared for psychiatric and physical reactivations, which are particularly prevalent after specific compounds, and acknowledge that standardized treatment protocols may overlook individual variations in response.